Watchlist Manager

Watchlist

Price: 29.87 CNY -2.45%

Market Cap: ¥14.3B

	Staidson Beijing BioPharmaceuticals Co Ltd SZSE:300204	CN
M	Malaysia Airports Holdings Bhd KLSE:AIRPORT	MY

Income Statement

Currency: CNY

	Dec-2010	Mar-2011	Jun-2011	Sep-2011	Dec-2011	Mar-2012	Jun-2012	Sep-2012	Dec-2012	Mar-2013	Jun-2013	Sep-2013	Dec-2013	Mar-2014	Jun-2014	Sep-2014	Dec-2014	Mar-2015	Jun-2015	Sep-2015	Dec-2015	Mar-2016	Jun-2016	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025
Revenue
Interest Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	0	1	1	1	1	1	1	0	0	0	0	0	1	1	1	1	1	1	1	0	0
Revenue	128 N/A	133 +3%	149 +13%	173 +15%	206 +19%	242 +18%	300 +24%	410 +37%	556 +36%	674 +21%	809 +20%	869 +8%	893 +3%	923 +3%	968 +5%	1 035 +7%	1 093 +6%	1 110 +2%	1 154 +4%	1 199 +4%	1 248 +4%	1 293 +4%	1 308 +1%	1 364 +4%	1 403 +3%	1 455 +4%	1 493 +3%	1 476 -1%	1 388 -6%	1 331 -4%	1 124 -16%	937 -17%	806 -14%	705 -12%	706 +0%	696 -1%	662 -5%	544 -18%	483 -11%	434 -10%	425 -2%	486 +14%	532 +9%	555 +4%	584 +5%	592 +1%	559 -6%	541 -3%	549 +1%	491 -11%	471 -4%	441 -7%	364 -17%	394 +8%	377 -4%	351 -7%	325 -7%	293 -10%	268 -9%	244 -9%
Gross Profit
Cost of Revenue	(15)	(16)	(18)	(21)	(25)	(27)	(30)	(32)	(29)	(37)	(52)	(52)	(44)	(53)	(50)	(58)	(61)	(70)	(71)	(73)	(68)	(77)	(77)	(80)	(71)	(81)	(81)	(84)	(77)	(92)	(88)	(85)	(75)	(80)	(84)	(86)	(81)	(77)	(78)	(77)	(78)	(96)	(104)	(114)	(116)	(127)	(116)	(110)	(102)	(89)	(89)	(85)	(75)	(74)	(72)	(66)	(62)	(65)	(63)	(58)
Gross Profit	113 N/A	117 +3%	131 +12%	152 +15%	181 +20%	215 +19%	270 +25%	377 +40%	527 +40%	637 +21%	756 +19%	818 +8%	849 +4%	870 +3%	918 +6%	976 +6%	1 032 +6%	1 040 +1%	1 083 +4%	1 127 +4%	1 180 +5%	1 216 +3%	1 231 +1%	1 285 +4%	1 333 +4%	1 374 +3%	1 412 +3%	1 392 -1%	1 311 -6%	1 239 -5%	1 036 -16%	852 -18%	731 -14%	625 -15%	623 0%	610 -2%	581 -5%	467 -20%	405 -13%	357 -12%	348 -3%	390 +12%	428 +10%	441 +3%	468 +6%	465 -1%	443 -5%	431 -3%	447 +4%	401 -10%	382 -5%	356 -7%	290 -19%	320 +11%	305 -5%	284 -7%	263 -8%	228 -13%	205 -10%	186 -9%
Operating Income
Operating Expenses	(48)	(53)	(62)	(73)	(77)	(92)	(110)	(206)	(359)	(451)	(576)	(667)	(748)	(790)	(870)	(870)	(849)	(854)	(858)	(901)	(937)	(1 007)	(1 015)	(1 051)	(1 053)	(1 114)	(1 144)	(1 124)	(1 026)	(998)	(830)	(715)	(604)	(555)	(587)	(589)	(590)	(530)	(510)	(488)	(523)	(558)	(600)	(660)	(703)	(701)	(693)	(682)	(672)	(673)	(701)	(631)	(658)	(642)	(520)	(476)	(297)	(263)	(267)	(245)
Selling, General & Administrative	(48)	(53)	(62)	(72)	(77)	(91)	(109)	(204)	(330)	(446)	(569)	(658)	(702)	(793)	(875)	(877)	(818)	(852)	(858)	(900)	(898)	(979)	(987)	(1 023)	(1 000)	(1 110)	(1 099)	(1 058)	(967)	(910)	(741)	(622)	(525)	(419)	(457)	(456)	(445)	(393)	(355)	(309)	(293)	(298)	(308)	(321)	(339)	(336)	(319)	(307)	(315)	(294)	(281)	(258)	(248)	(256)	(246)	(235)	(198)	(181)	(181)	(167)
Research & Development	0	0	0	0	0	0	0	0	(29)	0	0	0	(49)	0	0	0	(45)	0	0	0	(56)	0	0	0	(75)	0	0	(21)	(81)	0	0	(59)	(108)	(106)	(142)	(155)	(144)	(163)	(181)	(192)	(224)	(268)	(295)	(342)	(345)	(363)	(380)	(382)	(343)	(365)	(402)	(355)	(394)	(382)	(274)	(239)	(94)	(93)	(95)	(88)
Depreciation & Amortization	0	0	0	0	0	0	0	0	(0)	0	0	0	(0)	0	0	0	(0)	0	0	0	(0)	0	0	0	(0)	0	0	0	(11)	0	0	0	(14)	0	0	0	(18)	0	0	0	(20)	0	0	0	(22)	0	0	0	(23)	0	0	0	(21)	0	0	0	(15)	0	0	0
Other Operating Expenses	0	0	(0)	(0)	0	(1)	(1)	(2)	0	(6)	(7)	(8)	3	4	6	7	14	(1)	(1)	(1)	18	(27)	(28)	(28)	23	(5)	(45)	(44)	33	(88)	(89)	(34)	43	(30)	13	22	16	26	26	12	15	8	3	3	3	(2)	5	8	10	(15)	(18)	(18)	6	(4)	(0)	(2)	11	11	9	9
Operating Income	65 N/A	64 -2%	69 +9%	79 +14%	104 +31%	124 +19%	160 +29%	172 +7%	168 -2%	186 +11%	180 -3%	151 -16%	101 -33%	80 -20%	48 -40%	106 +120%	183 +72%	187 +2%	225 +20%	226 +0%	243 +8%	210 -14%	216 +3%	234 +8%	280 +20%	260 -7%	268 +3%	268 +0%	285 +6%	242 -15%	206 -15%	138 -33%	127 -8%	70 -45%	36 -48%	22 -40%	(10) N/A	(63) -545%	(105) -66%	(132) -26%	(175) -33%	(168) +4%	(172) -2%	(219) -27%	(235) -7%	(235) 0%	(251) -6%	(251) 0%	(224) +11%	(272) -21%	(319) -17%	(275) +14%	(368) -34%	(321) +13%	(215) +33%	(192) +11%	(34) +82%	(35) -1%	(61) -77%	(59) +4%
Pre-Tax Income
Interest Income Expense	(1)	(1)	3	10	16	24	27	27	26	24	21	24	24	28	34	34	21	38	40	39	19	35	33	35	15	43	48	50	18	51	51	51	23	48	43	37	30	25	23	19	18	18	16	19	22	18	15	9	6	5	4	3	1	1	(1)	0	0	(0)	0	(5)
Non-Reccuring Items	0	0	0	0	(0)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(25)	0	0	0	0	0	0	0	(0)	0	0	0	(0)	0	0	0	(0)	0	0	0	2	0	0	0	(0)	(0)	(0)	(0)	(24)	0	0	0	0	0	0	0	0	0	1	1
Gain/Loss on Disposition of Assets	0	0	0	0	0	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0	0	0	0	(0)	(0)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	4	4	5	3	4	5	5	6	1	(0)	(1)	7	0	8	10	3	29	29	27	26	5	5	5	5	1	1	1	0	(0)	(0)	(0)	(1)	1	1	1	2	0	0	(5)	(5)	(5)	(5)	(0)	0	0	0	(0)	(1)	(0)	(0)	1	0	(0)	(1)	(1)	(1)	(1)	(0)	(0)	(0)
Pre-Tax Income	68 N/A	67 -1%	77 +15%	92 +19%	124 +35%	153 +23%	192 +26%	204 +6%	194 -5%	210 +8%	200 -5%	181 -9%	132 -27%	116 -12%	92 -21%	143 +56%	233 +62%	254 +9%	292 +15%	291 0%	243 -17%	250 +3%	254 +2%	273 +8%	296 +8%	303 +2%	316 +4%	319 +1%	303 -5%	292 -4%	257 -12%	187 -27%	151 -19%	119 -21%	79 -33%	60 -25%	20 -66%	(39) N/A	(87) -125%	(118) -35%	(160) -36%	(155) +3%	(157) -1%	(200) -27%	(213) -7%	(217) -2%	(236) -8%	(242) -3%	(243) 0%	(267) -10%	(314) -17%	(271) +13%	(366) -35%	(321) +12%	(216) +33%	(193) +11%	(34) +82%	(35) -2%	(60) -72%	(63) -4%
Net Income
Tax Provision	(11)	(11)	(13)	(14)	(20)	(23)	(30)	(33)	(34)	(39)	(34)	(32)	(23)	(19)	(18)	(25)	(38)	(44)	(48)	(46)	(34)	(36)	(36)	(36)	(41)	(36)	(38)	(44)	(42)	(43)	(40)	(30)	(17)	(12)	(7)	(4)	7	13	3	5	27	27	39	39	76	76	76	76	46	46	46	44	(32)	0	(32)	(31)	(113)	0	(113)	(113)
Income from Continuing Operations	58	56	64	78	104	130	162	171	160	171	166	150	110	97	74	118	195	210	244	245	209	214	217	238	255	268	278	275	260	249	217	158	134	106	73	56	27	(25)	(83)	(112)	(133)	(128)	(118)	(161)	(137)	(142)	(160)	(166)	(197)	(221)	(268)	(227)	(399)	(354)	(249)	(223)	(148)	(148)	(174)	(176)
Income to Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	3	2	3	4	4	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	5	7	10
Net Income (Common)	58 N/A	56 -2%	64 +14%	78 +21%	104 +34%	130 +24%	162 +25%	171 +6%	160 -7%	171 +7%	166 -3%	150 -10%	110 -27%	97 -11%	74 -24%	118 +61%	195 +65%	210 +8%	244 +16%	245 +0%	211 -14%	216 +2%	220 +2%	241 +9%	257 +7%	271 +5%	282 +4%	278 -1%	263 -5%	251 -5%	217 -13%	158 -27%	134 -15%	106 -21%	73 -31%	56 -23%	27 -52%	(25) N/A	(83) -229%	(112) -34%	(133) -19%	(128) +4%	(118) +8%	(161) -36%	(137) +14%	(142) -3%	(160) -13%	(166) -4%	(197) -18%	(221) -12%	(268) -21%	(227) +15%	(399) -76%	(354) +11%	(249) +30%	(223) +10%	(145) +35%	(143) +1%	(166) -16%	(166) 0%
EPS (Diluted)	0.16 N/A	0.16 N/A	0.17 +6%	0.18 +6%	0.24 +33%	0.28 +17%	0.34 +21%	0.36 +6%	0.34 -6%	0.35 +3%	0.34 -3%	0.31 -9%	0.23 -26%	0.21 -9%	0.16 -24%	0.25 +56%	0.41 +64%	0.44 +7%	0.52 +18%	0.53 +2%	0.44 -17%	0.47 +7%	0.47 N/A	0.51 +9%	0.54 +6%	0.56 +4%	0.59 +5%	0.58 -2%	0.55 -5%	0.53 -4%	0.48 -9%	0.34 -29%	0.28 -18%	0.23 -18%	0.16 -30%	0.12 -25%	0.06 -50%	-0.05 N/A	-0.18 -260%	-0.24 -33%	-0.28 -17%	-0.27 +4%	-0.24 +11%	-0.33 -38%	-0.29 +12%	-0.3 -3%	-0.34 -13%	-0.35 -3%	-0.41 -17%	-0.46 -12%	-0.56 -22%	-0.47 +16%	-0.84 -79%	-0.74 +12%	-0.52 +30%	-0.47 +10%	-0.3 +36%	0 N/A	-0.34 N/A	-0.34 N/A

Income Statement Balance Sheet Cash Flow Statement

Staidson Beijing BioPharmaceuticals Co Ltd
SZSE:300204

Income Statement

Earnings Waterfall
Staidson Beijing BioPharmaceuticals Co Ltd

Income Statement
Staidson Beijing BioPharmaceuticals Co Ltd

See Also

Company

Help

Tools

Stocks

Staidson Beijing BioPharmaceuticals Co Ltd SZSE:300204

Income Statement

Earnings Waterfall Staidson Beijing BioPharmaceuticals Co Ltd

Income Statement Staidson Beijing BioPharmaceuticals Co Ltd

See Also

Company

Help

Tools

Stocks

Staidson Beijing BioPharmaceuticals Co Ltd
SZSE:300204

Earnings Waterfall
Staidson Beijing BioPharmaceuticals Co Ltd

Income Statement
Staidson Beijing BioPharmaceuticals Co Ltd